Abstract |
Pharmacologic intervention in the management of allergic conjunctivitis was evaluated with different topical ocular agents in man. Their effect can be precisely assessed with the conjunctival provocation test ( CPT). A potent specific H1-receptor antagonist, 0.05% mequitazine eye-drops, was tested in a double-blind randomized, placebo-controlled study using CPT with grass pollen allergens. Twenty healthy subjects allergic to grass pollen were included outside the pollen season after a positive CPT screening. They received one drop of 0.05% mequitazine in one eye and the vehicle in the contralateral eye in a random order, four times daily for 5 days. CPT was performed 15 min after the last instillation, and the threshold dose inducing a positive reaction was determined. Results were given by Abelson's composite score including redness, chemosis, tearing, and itching. Topical 0.05% mequitazine significantly reduced the composite score compared to placebo. The allergen threshold concentration which induced the positive conjunctival reaction was higher in mequitazine pretreated eyes. No side-effect was reported. These data clearly suggest that mequitazine has potential to treat allergic conjunctivitis.
|
Authors | L Persi, O Dupin, B Arnaud, C Trinquand, F B Michel, J Bousquet |
Journal | Allergy
(Allergy)
Vol. 52
Issue 4
Pg. 451-4
(Apr 1997)
ISSN: 0105-4538 [Print] Denmark |
PMID | 9188930
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Allergens
- Histamine H1 Antagonists
- Phenothiazines
- mequitazine
|
Topics |
- Adult
- Allergens
- Conjunctivitis, Allergic
(drug therapy, etiology, immunology)
- Double-Blind Method
- Histamine H1 Antagonists
(therapeutic use)
- Humans
- Phenothiazines
(therapeutic use)
- Poaceae
- Pollen
- Skin Tests
|